CytoDyn appoints Karen J. Brunke, Ph.D. as director effective March 27, 2022

CytoDyn Inc.

Dr. Brunke fills the vacancy created by Harish Seethamraju's resignation in December 2021.
She brings over 30 years of biotech experience, currently EVP at Jaguar Health (JAGX).
Board expects to appoint her to Compensation Committee; compensation per nonemployee director policy.
No transactions requiring disclosure under Item 404(a) between Dr. Brunke and the Company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Karen J. Brunke

director

CYDY · CytoDyn Inc.

Effective: 2022-03-27
Filed: March 30, 2022, 7:59 PM ET

On March 27, 2022, the Board of Directors (the “Board”) of CytoDyn Inc. (the “Company”) approved the appointment of Karen J. Brunke, Ph.D., as a director of the Company, subject to satisfactory completion of a background check.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen J. Brunke was appointed as director at CytoDyn Inc..

Action: appointed
Role: director

Exact text from the filing

On March 27, 2022, the Board of Directors (the “Board”) of CytoDyn Inc. (the “Company”) approved the appointment of Karen J. Brunke, Ph.D., as a director of the Company, subject to satisfactory completion of a background check.

View on SEC.gov

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-090064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.